Clinical Research Center s.r.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The Clinical Research Center s.r.o. is conducting trials that focus on Atopic Dermatitis, evaluating a novel biologic therapy to improve skin health in moderate‑to‑severe patients.
- Placebo‑controlled efficacy assessment of rocatinlimab
- Use of the Validated Investigator’s Global Assessment (vIGA‑AD) as primary endpoint
- Evaluation of the Eczema Area and Severity Index (EASI) scores
- Monotherapy approach in a double‑blind Phase 3 design
These studies aim to demonstrate that the new treatment can significantly reduce disease severity and improve quality of life for participants in Pardubice.
Cardiovascular Diseases
Research at the site targets Heart Failure With Preserved or Mildly Reduced Ejection Fraction combined with Obesity, testing an innovative agent to lower cardiovascular risk.
- Adjunct therapy with maridebart cafraglutide alongside standard care
- Composite endpoint of heart‑failure hospitalization, urgent visits, and cardiovascular death
- Inclusion of participants with BMI ≥ 30 kg/m²
- Phase 3 double‑blind, placebo‑controlled design
The goal is to show that this medication can reduce serious heart‑failure events and improve outcomes for patients with the specified cardiac profile at the Clinical Research Center s.r.o..
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinical Research Center s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite) | Amgen Inc. | Phase III | Not Recruiting | Apr 2023 | Sep 2024 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rocatinlimab | 3 | Unknown | 2023-04-25 | 2023-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.